Lek aborts investment in new factory at Prevalje

Ljubljana, 2 September - Lek, the Slovenian subsidiary of pharma company Novartis, has aborted its investment into expanding production in the town of Prevalje, north, where it has been present for more than 40 years. The decision seems to be have been made due to lower demand for generics following an in-depth analysis and studying all options.

Prevalje
Lek's additional production facility for broad-spectrum antibiotics, a EUR 150-million investment which has been aborted.
Photo: Vesna Pušnik Brezovnik/STA
File photo

The rest of this news item is available to subscribers.
The news item consists of 2.093 characters (without spaces) or 412 words words.

Buy the news item. Price: 2 tokens; on account: 0 tokens.

eho/jes/uk/vpu/ep
© STA, 2019